Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Koninklijke Philips NV (PHG) Price & Performance

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETFTrade
Koninklijke Philips NVTrade

Price performance (Past 24H)

Key statistics

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Koninklijke Philips NV — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $17.82, while Koninklijke Philips NV trades at $26.3 (market cap $25.89B). The key difference: Koninklijke Philips NV pays a 3.81% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none, and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.

PDBCPHG
52-Week High
$18.91$32.91
52-Week Low
$12.90$25.02
Market Cap
$25.89B
Sector
Health
Enterprise Value
$32.18B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

PDBC, the Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF, trades at $17.65, up 2.32% today, reflecting strong commodity momentum. The technical outlook is bullish with moving averages signaling strength, though RSI levels suggest potential overbought conditions. Recent news highlights institutional accumulation, such as Geneos Wealth Management increasing its stake by 150.6% in Q1 2026 (Defense World, 2026-07-19). The fund has delivered significant returns, up 37% since March 2024, driven by energy price surges and supply disruptions.

The outlook for PDBC remains positive as a diversified commodities play and inflation hedge, but risks include commodity price volatility and the fund's structural costs. Momentum may weaken if oil prices retreat, as noted in a recent downgrade to hold (Seeking Alpha, 2026-06-11). Investors should weigh the fund's tax advantages against roll costs and cyclical commodity exposure.

Koninklijke Philips NV

PHG trades at $26.58, down 1.37% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported net income of $895 million in 2025, a significant recovery from prior losses, with a net margin of 5.5%. Recent FDA clearances for medical devices and AI integrations highlight ongoing innovation. Cash flow from operations remains positive at $1.17 billion for 2025, though net cash flow declined to $403 million.

The outlook is mixed: analyst consensus is neutral with 59% hold ratings, reflecting caution despite recent profitability improvements. Key risks include high debt levels, with debt-to-asset ratio at 25.44% in 2025, and competitive pressures in health technology. Upside potential hinges on execution of AI-driven growth initiatives and margin expansion, as noted in Seeking Alpha analysis on 2026-05-20.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF

The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.

Read more on PDBC

About Koninklijke Philips NV

Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.

Read more on PHG